Advertisement

Topics

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

2014-08-27 03:49:43 | BioPortfolio

Summary

This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.

Description

We are using depression symptom measurements and measurements of brain electrical activity (EEG) to determine what factors may influence whether a patient is likely to show a response to antidepressant medication, placebo, or only clinical visits (without the use of pills) during a treatment trial for depression.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Conditions

Depression

Intervention

venlafaxine (Effexor), duloxetine (Cymbalta), escitalopram (Lexapro), placebo

Location

UCLA Laboratory of Brain, Behavior, and Pharmacology
Los Angeles
California
United States
90024

Status

Suspended

Source

University of California, Los Angeles

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:49:43-0400

Clinical Trials [1419 Associated Clinical Trials listed on BioPortfolio]

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

The purposes of this study are to determine: - The safety of duloxetine and any side effects that might be associated with it. - How duloxetine compares to escitalopram and placebo...

Duloxetine vs. Active Comparator for the Treatment of Depression

How duloxetine compares to a medication currently available for the treatment of depression in the treatment of patients with major depressive disorder. The safety of duloxetine and any s...

Lexapro in the Treatment of Patients With Postpartum Depression

The purpose of this study is to determine if Escitalopram (Lexapro) is effective in the treatment of postpartum depression.

Duloxetine for Chronic Depression: a Double-blind Study

The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by th...

Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia

Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treat...

PubMed Articles [3353 Associated PubMed Articles listed on BioPortfolio]

Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay.

The aim of this study was to determine the steroidogenic endocrine disrupting effect of the three most widely used serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol, usi...

Is Venlafaxine More Effective than Escitalopram and Nortriptyline in the Management of Painful Symptoms in Patients with Major Depression?

Background Conflicting data regarding the efficacy of antidepressants of different mechanism of action on unexplained painful physical symptoms (UPPS) in depression have been published so far. Objecti...

Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment.

Immune system activation and neuroinflammation appear to play a key role in the pathophysiology and treatment of bipolar depression (BDD). This study is the first to analyze blood levels of the pro-in...

Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-18FFMeNER-D2.

The norepinephrine transporter in the brain has been targeted in the treatment of psychiatric disorders. Duloxetine is a serotonin and norepinephrine reuptake inhibitor that has been widely used for t...

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved...

Medical and Biotech [MESH] Definitions

Decompression external to the body, most often the slow lessening of external pressure on the whole body (especially in caisson workers, deep sea divers, and persons who ascend to great heights) to prevent DECOMPRESSION SICKNESS. It includes also sudden accidental decompression, but not surgical (local) decompression or decompression applied through body openings.

Depression in POSTPARTUM WOMEN, usually within four weeks after giving birth (PARTURITION). The degree of depression ranges from mild transient depression to neurotic or psychotic depressive disorders. (From DSM-IV, p386)

Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.

More From BioPortfolio on "Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial